TY - JOUR
T1 - Cancer nanomedicine meets immunotherapy
T2 - opportunities and challenges
AU - Sun, Qingxue
AU - Bai, Xiangyang
AU - Sofias, Alexandros Marios
AU - van der Meel, Roy
AU - Ruiz-Hernandez, Eduardo
AU - Storm, Gert
AU - Hennink, Wim E
AU - De Geest, Bruno
AU - Kiessling, Fabian
AU - Yu, Hai-Jun
AU - Lammers, Twan
AU - Shi, Yang
PY - 2020/7
Y1 - 2020/7
N2 - Cancer nanomedicines have shown promise in combination immunotherapy, thus far mostly preclinically but also already in clinical trials. Combining nanomedicines with immunotherapy aims to reinforce the cancer-immunity cycle, via potentiating key steps in the immune reaction cascade, namely antigen release, antigen processing, antigen presentation, and immune cell-mediated killing. Combination nano-immunotherapy can be realized via three targeting strategies, i.e., by targeting cancer cells, targeting the tumor immune microenvironment, and targeting the peripheral immune system. The clinical potential of nano-immunotherapy has recently been demonstrated in a phase III trial in which nano-albumin paclitaxel (Abraxane®) was combined with atezolizumab (Tecentriq®) for the treatment of patients suffering from advanced triple-negative breast cancer. In the present paper, besides strategies and initial (pre)clinical success stories, we also discuss several key challenges in nano-immunotherapy. Taken together, nanomedicines combined with immunotherapy are gaining significant attention, and it is anticipated that they will play an increasingly important role in clinical cancer therapy.
AB - Cancer nanomedicines have shown promise in combination immunotherapy, thus far mostly preclinically but also already in clinical trials. Combining nanomedicines with immunotherapy aims to reinforce the cancer-immunity cycle, via potentiating key steps in the immune reaction cascade, namely antigen release, antigen processing, antigen presentation, and immune cell-mediated killing. Combination nano-immunotherapy can be realized via three targeting strategies, i.e., by targeting cancer cells, targeting the tumor immune microenvironment, and targeting the peripheral immune system. The clinical potential of nano-immunotherapy has recently been demonstrated in a phase III trial in which nano-albumin paclitaxel (Abraxane®) was combined with atezolizumab (Tecentriq®) for the treatment of patients suffering from advanced triple-negative breast cancer. In the present paper, besides strategies and initial (pre)clinical success stories, we also discuss several key challenges in nano-immunotherapy. Taken together, nanomedicines combined with immunotherapy are gaining significant attention, and it is anticipated that they will play an increasingly important role in clinical cancer therapy.
KW - nanomedicine
KW - immunotherapy
KW - targeting
KW - combination therapy
KW - clinical translation
U2 - 10.1038/s41401-020-0448-9
DO - 10.1038/s41401-020-0448-9
M3 - Review article
C2 - 32555445
SN - 0253-9756
VL - 41
SP - 954
EP - 958
JO - Acta Pharmacologica Sinica
JF - Acta Pharmacologica Sinica
IS - 7
ER -
